Neil F. McFarlane, who serves as president and chief executive officer of Zevra Therapeutics (NASDAQ: ZVRA), executed a sale of company common stock on February 9, 2026. The disposition comprised 14,625 shares and generated proceeds of approximately $125,185. The transactions were completed at a weighted average price of $8.5597 per share, with individual trades occurring within a range of $8.39 to $8.67.
Prior to the sale, on February 7, McFarlane exercised 37,500 restricted stock units, which immediately converted into 37,500 shares of Zevra common stock. The sequence of exercising RSUs followed by a partial sale of shares is reflected in the filings disclosed for the early February dates.
Market context and valuation indicators
Zevra's share price is trading at $8.61, below its 52-week peak of $13.16. Market capitalization stands at $484.7 million. According to InvestingPro's analysis cited in company research, Zevra appears undervalued on a Fair Value assessment. The same analysis notes that sell-side analysts have issued price targets spanning $18 to $26 per share.
InvestingPro's broader assessment of the company flags Zevra with an overall "GOOD" score. The report highlights the firm's balance sheet position as having more cash than debt and notes that the company is scheduled to report its next quarterly results on March 11, 2026.
Corporate developments
In separate corporate news, Zevra has entered an exclusive expanded access distribution agreement with Uniphar. The agreement broadens the geographic reach of the company's existing expanded access program for Miplyffa (arimoclomol), which is used for patients with Niemann-Pick Disease Type C. Following the announcement, H.C. Wainwright reiterated its Buy rating on Zevra Therapeutics and maintained a price target of $26.00.
Company statements and analyst commentary presented alongside these recent transactions indicate ongoing efforts to expand patient access to treatments and reflect continued analyst interest in the equity, as signaled by the reiterated Buy rating.
What to watch next
- Upcoming earnings on March 11, 2026, which will provide updated operating results and guidance.
- Any further insider transactions or filings that clarify ownership changes following the RSU exercise and share sale.
- Implementation details and territorial scope of the expanded access distribution agreement with Uniphar.